نتائج البحث - "Rossella Renso"

المساهمون: Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F

مصطلحات موضوعية: ruxolitinib, myelofibrosis, Hematology, Iron Chelating Agents, Benzoates, cancer, deferasirox, iron overload, Pyrimidines, myelofibrosi, MED/15 - MALATTIE DEL SANGUE, Primary Myelofibrosis, Nitriles, Humans, Pyrazoles, Retrospective Studies

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c156776f50e229cb57d6b834ba5609b
http://hdl.handle.net/20.500.11769/522099

4

ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine

المساهمون: Fontana, D, Mauri, M, Renso, R, Docci, M, Crespiatico, I, Rost, L, Jang, M, Niro, A, D'Aliberti, D, Massimino, L, Bertagna, M, Zambrotta, G, Bossi, M, Citterio, S, Crescenzi, B, Fanelli, F, Cassina, V, Corti, R, Salerno, D, Nardo, L, Chinello, C, Mantegazza, F, Mecucci, C, Magni, F, Cavaletti, G, Bruheim, P, Rea, D, Larsen, S, Piazza, R, Gambacorti-Passerini, C

مصطلحات موضوعية: business.industry, Kinase, Somatic cell, Immunology, Mutator phenotype, Chronic myelomonocytic leukemia, Cell Biology, Hematology, medicine.disease, Biochemistry, medicine, Atypical chronic myeloid leukemia, Cancer research, Eosinophilia, Phosphorylation, Systemic mastocytosis, medicine.symptom, business, ETNK1, chronic myeloid leukemia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578629e64fd8f76dcfc678e902a04e43
https://hdl.handle.net/11380/1249547

5

A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation

المؤلفون: Rocco Piazza, Matteo Parma, Rossella Renso, Elisa Diral, Paola Perfetti, Sara Pezzatti, Carlo Gambacorti-Passerini, Deborah D'Aliberti, Elisabetta Terruzzi, Elena Maria Elli

المساهمون: Diral, E, Parma, M, Renso, R, Pezzatti, S, Terruzzi, E, Perfetti, P, D'Aliberti, D, Gambacorti Passerini, C, Piazza, R, Elli, E

مصطلحات موضوعية: Cancer Research, business.industry, Hematology, medicine.disease, TEMPI syndrome, autologous stem cell transplantation, Monoclonal gammopathy, erythropoietin, smoldering multiple myeloma, Monoclonal gammopathy, Autologous stem-cell transplantation, TEMPI syndrome, Oncology, Proteasome, Refractory, Erythropoietin, medicine, Cancer research, medicine.symptom, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3061d311c1ca540bd4e734e2f4e4e844
http://hdl.handle.net/10281/284172

6

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

المساهمون: Fontana, D, Mauri, M, Renso, R, Docci, M, Crespiatico, I, Rost, L, Jang, M, Niro, A, D'Aliberti, D, Massimino, L, Bertagna, M, Zambrotta, G, Bossi, M, Citterio, S, Crescenzi, B, Fanelli, F, Cassina, V, Corti, R, Salerno, D, Nardo, L, Chinello, C, Mantegazza, F, Mecucci, C, Magni, F, Cavaletti, G, Bruheim, P, Rea, D, Larsen, S, Gambacorti-Passerini, C, Piazza, R

المصدر: Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Fontana, D, Mauri, M, Renso, R, Docci, M, Crespiatico, I, Røst, L M, Jang, M, Niro, A, D’aliberti, D, Massimino, L, Bertagna, M, Zambrotta, G, Bossi, M, Citterio, S, Crescenzi, B, Fanelli, F, Cassina, V, Corti, R, Salerno, D, Nardo, L, Chinello, C, Mantegazza, F, Mecucci, C, Magni, F, Cavaletti, G, Bruheim, P, Rea, D, Larsen, S, Gambacorti-passerini, C & Piazza, R 2020, ' ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine ', Nature Communications, vol. 11, no. 1, 5938 . https://doi.org/10.1038/s41467-020-19721-w

مصطلحات موضوعية: 0301 basic medicine, Myeloid, Cancer therapy, Somatic cell, Succinic Acid, General Physics and Astronomy, Cell Line, Cell Respiration, DNA Breaks, Electron Transport Complex II, Ethanolamines, Humans, Leukemia, Myeloid, Mitochondria, Mutation, Phenotype, Phosphotransferases (Alcohol Group Acceptor), Reactive Oxygen Species, Tigecycline, Mitochondrion, medicine.disease_cause, MITOCHONDRIAL, 0302 clinical medicine, PHOSPHATIDYLETHANOLAMINE, Ethanolamine, PHOSPHOMETABOLOME, Multidisciplinary, Leukemia, Hyperactivation, Molecular medicine, Chemistry, DNA Break, Cell biology, 030220 oncology & carcinogenesis, Phosphorylation, Reactive Oxygen Specie, Intracellular, Human, DNA damage, Science, HIGH-THROUGHPUT, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, medicine, TANDEM MASS-SPECTROMETRY, PATHWAYS, LEUKEMIA, LIPIDOME, REPAIR, Haematological cancer, General Chemistry, 030104 developmental biology

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9daa2965213b7e056a4bf82b15332df7
http://hdl.handle.net/10281/298474

7

Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy

المؤلفون: Carolina Steidl, Luisa Verga, Rossella Renso, Geeta G. Sharma, Filippo Brioschi, Luca Mologni, Elisa Bossi, Andrea Aroldi, Rocco Piazza, Carlo Gambacorti-Passerini, Lara Mussolin, Diletta Fontana, Silvia Baretta

المساهمون: Bossi, E, Aroldi, A, Brioschi, F, Steidl, C, Baretta, S, Renso, R, Verga, L, Fontana, D, Sharma, G, Mologni, L, Mussolin, L, Piazza, R, Gambacorti Passerini, C

مصطلحات موضوعية: Chemotherapy, ALK-Positive Anaplastic Large Cell Lymphoma, Crizotinib, business.industry, medicine.medical_treatment, Large cell, Hematology, medicine.disease, Lymphoma, Refractory, Cancer research, Medicine, Anaplastic lymphoma kinase, crizotinib, anaplastic lymphoma kinase (ALK) positive, anaplastic large‐cell lymphoma (ALCL), relapsed, refractory, business, Survival rate, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bb2e5e4f31094703f4dcf0586fc7f81
http://hdl.handle.net/11577/3353155

8

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea

المؤلفون: Carlo Gambacorti-Passerini, Andrea Aroldi, Rossella Renso, Elena Maria Elli, Pietro Pioltelli

المساهمون: Renso, R, Aroldi, A, Pioltelli, P, Gambacorti-Passerini, C, Elli, E

المصدر: Blood Cancer Journal, Vol 8, Iss 6, Pp 1-3 (2018)
Blood Cancer Journal

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, medicine.medical_treatment, myeloproliferative neoplasm, Drug Resistance, Drug resistance, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Text mining, MED/15 - MALATTIE DEL SANGUE, Internal medicine, Correspondence, medicine, Humans, Hydroxyurea, Antineoplastic Agents, Alkylating, Busulfan, Survival analysis, Aged, Chemotherapy, Second line treatment, Essential thrombocythemia, business.industry, Age Factors, Hematology, thrombocythemia, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Survival Analysis, Term (time), Treatment Outcome, 030220 oncology & carcinogenesis, Retreatment, Female, business, 030215 immunology, medicine.drug, Thrombocythemia, Essential

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b08252da5e6cb90d0dc9f6fedcc258e
http://link.springer.com/article/10.1038/s41408-018-0091-6

Find this article in full text from ProQuest

9

Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients

المصدر: Blood advances 3 (2019): 3196–3200. doi:10.1182/bloodadvances.2019000646
info:cnr-pdr/source/autori:Margherita Maffioli and Toni Giorgino and Barbara Mora and Alessandra Iurlo and Elena Elli and Maria Chiara Finazzi and Marianna Caramella and Elisa Rumi and Maria Cristina Carraro and Nicola Polverelli and Mariella D'Adda and Simona Malato and Marianna Rossi and Alfredo Molteni and Alessandro Vismara and Cinzia Sissa and Francesco Spina and Michela Anghilieri and Daniele Cattaneo and Rossella Renso and Marta Bellini and Maria Luisa Pioltelli and Chiara Cavalloni and Daniela Barraco and Raffaella Accetta and Lorenza Bert`u and Matteo Giovanni Della Porta and Francesco Passamonti/titolo:Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients/doi:10.1182%2Fbloodadvances.2019000646/rivista:Blood advances/anno:2019/pagina_da:3196/pagina_a:3200/intervallo_pagine:3196–3200/volume:3

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89a5b41a649ae26b37c0e831ce0956bf
https://hdl.handle.net/11379/569789

10

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

المصدر: Blood. 134:839-839

مصطلحات موضوعية: medicine.medical_specialty, Ruxolitinib, Thrombocytosis, Anemia, business.industry, Surrogate endpoint, Immunology, Deferasirox, Cell Biology, Hematology, medicine.disease, Biochemistry, Internal medicine, Concomitant, medicine, In patient, business, Myelofibrosis, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2928715e35574acc2a6978e17638fd47
https://doi.org/10.1182/blood-2019-127488

تنقيح النتائج